Dallas-based has announced ninety-eight grants totaling $30.7 million in support of breast cancer research.
Awarded to researchers and institutions in twenty-seven states and eight countries, the 2017 grants, which include $17.6 million for early-career investigators, will support research related to new screening technologies, treatments for metastatic and aggressive types of breast cancer, and disparities in breast cancer outcomes. Metastatic breast cancer — in which the disease spreads to other parts of the body — is responsible for almost all the forty thousand annual breast cancer deaths in the United States.
The organization also announced that for the first time it is giving the public an opportunity to directly fund specific research by participating in a crowdfunding initiative on its website. During October — — Komen will highlight four metastatic breast cancer researchers and encourage donations for their research, with an opportunity to have the donations matched.
"We are focused on new treatments, ways to overcome drug resistance in breast cancer patients, and a better understanding of how and why breast cancer spreads, so we can better treat metastatic breast cancer or prevent it all together," said Komen interim president and CEO Ellen Willmott. "This focus on aggressive and metastatic disease is the foundation of our Bold Goal to reduce breast cancer deaths by 50 percent by 2026."